Literature DB >> 18298329

Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.

Karine Assié1, Arnaud Dieudonné, Isabelle Gardin, Irène Buvat, Hervé Tilly, Pierre Vera.   

Abstract

UNLABELLED: We compared the radiation-absorbed dose obtained from a two dimensional (2D) protocol, based on planar whole-body (WB) scans and fixed reference organ masses with dose estimates, using a 3D single-photon emission computed tomography (SPECT) imaging protocol and patient-specific organ masses.
METHODS: Six (6) patients with follicular non-Hodgkin's lymphoma underwent a computed tomography (CT) scan, 5 2D planar WB, and 5 SPECT scans between days 0 and 6 after the injection of (111)In-ibritumomab tiuxetan. The activity values in the liver, spleen, and kidneys were calculated from the 2D WB scans, and also from the 3D SPECT images reconstructed, using quantitative image processing. Absorbed doses after the administration of (90)Y-ibritumomab tiuxetan were calculated from the (111)In WB activity values combined with reference organ masses and also from the SPECT activity values and organ masses as estimated from the patient CT scan. To assess the quantitative accuracy of the WB and SPECT scans, an abdominal phantom was also studied.
RESULTS: The differences between organ masses estimated from the patient CT and from the reference MIRD models were between -10% and +98%. Using the phantom, errors in organ and tumor activity estimates were between -86% and 10% for the WB protocol and between -43% and -6% for the SPECT protocol. Patient liver, spleen, and kidney activity values determined from SPECT were systematically less than those from the WB scans. Radiation-absorbed doses calculated with the 3D protocol were systematically lower than those calculated from the WB protocol (29%+/-26%, 73%+/-26%, and 33%+/-53% differences in the liver, spleen, and kidney, respectively), except in the kidneys of 2 patients and in the liver of 1 patient.
CONCLUSIONS: Accounting for patient-specific organ mass and using SPECT activity quantification have both a great impact on estimated absorbed doses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18298329     DOI: 10.1089/cbr.2007.372

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  10 in total

1.  Effects of shortened acquisition time on accuracy and precision of quantitative estimates of organ activity.

Authors:  Bin He; Eric C Frey
Journal:  Med Phys       Date:  2010-04       Impact factor: 4.071

2.  EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting.

Authors:  M Lassmann; C Chiesa; G Flux; M Bardiès
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-27       Impact factor: 9.236

3.  EQPlanar: a maximum-likelihood method for accurate organ activity estimation from whole body planar projections.

Authors:  N Song; B He; R L Wahl; E C Frey
Journal:  Phys Med Biol       Date:  2011-08-03       Impact factor: 3.609

Review 4.  Accuracy and precision of radioactivity quantification in nuclear medicine images.

Authors:  Eric C Frey; John L Humm; Michael Ljungberg
Journal:  Semin Nucl Med       Date:  2012-05       Impact factor: 4.446

5.  MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy.

Authors:  Yuni K Dewaraja; Eric C Frey; George Sgouros; A Bertrand Brill; Peter Roberson; Pat B Zanzonico; Michael Ljungberg
Journal:  J Nucl Med       Date:  2012-06-28       Impact factor: 10.057

6.  Fine-resolution voxel S values for constructing absorbed dose distributions at variable voxel size.

Authors:  Arnaud Dieudonné; Robert F Hobbs; Wesley E Bolch; George Sgouros; Isabelle Gardin
Journal:  J Nucl Med       Date:  2010-09-16       Impact factor: 10.057

7.  A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin).

Authors:  Massimiliano Pacilio; Margherita Betti; Francesco Cicone; Carolina Del Mastro; Livia Montani; Laura Chiacchiararelli; Alessia Monaco; Enrico Santini; Francesco Scopinaro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

8.  Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies.

Authors:  Bin He; Richard L Wahl; George Sgouros; Yong Du; Heather Jacene; Wayne R Kasecamp; Ian Flinn; Richard J Hammes; Jay Bianco; Brad Kahl; Eric C Frey
Journal:  Med Phys       Date:  2009-05       Impact factor: 4.071

9.  Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma.

Authors:  Kohei Hanaoka; Makoto Hosono; Yoichi Tatsumi; Kazunari Ishii; Sung-Woon Im; Norio Tsuchiya; Kenta Sakaguchi; Itaru Matsumura
Journal:  EJNMMI Res       Date:  2015-03-14       Impact factor: 3.138

10.  Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP.

Authors:  Breelyn A Wilky; David M Loeb
Journal:  Clin Exp Pharmacol       Date:  2013-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.